Ирска - Енглески - HPRA (Health Products Regulatory Authority)

orion corporation - methotrexate - tablet - 10 milligram(s) - other immunosuppressants; methotrexate

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

orion pharma (uk) ltd - methotrexate - oral tablet - 2.5mg

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

orion pharma (uk) ltd - methotrexate - oral tablet - 10mg

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - methotrexate - oral tablet - 10mg

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 7.5 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Малта - Енглески - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - methotrexate - solution for injection - methotrexate 25 mg/ml - antineoplastic agents

Малта - Енглески - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - methotrexate - solution for injection - methotrexate 25 mg/ml - antineoplastic agents

Малта - Енглески - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - methotrexate - solution for injection - methotrexate 25 mg/ml - antineoplastic agents

Израел - Енглески - Ministry of Health

novartis israel ltd - methotrexate - solution for injection - methotrexate 20 mg/ml - methotrexate - methotrexate - psoriasis: methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well established according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease- modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequatecrohn’s disease: mild to moderate crohn's disease either alone or in combination with corticosteroids in adult patients ref

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - methotrexate - solution for injection in pre-filled syringe - 25 mg/ml - antineoplastic and immunomodulating agents, antimetabolites, folic acid analogues - active rheumatoid arthritis in adult patients; polyarthritic forms of severe, active juvenile idiopathic arthritis (jia), when the response to non-steroidal antiinflammatory drugs (nsaids) has been inadequate; severe forms of psoriasis vulgaris, particularly of the plaque type, which cannot be sufficiently treated with conventional therapy such as phototherapy, puva, and retinoids, and severe psoriatic arthritis